Activated charcoal neutralization restores accurate Model for End-Stage Liver Disease and Child-Pugh scores in patients with cirrhosis on direct oral anticoagulant therapy
These findings highlight the importance of identifying patients on DOAC therapy and implementing neutralization techniques to avoid overestimating disease severity. DOAC-Stop effectively eliminates rivaroxaban- and apixaban-related interference, even in this specific population of patients with cirrhosis who sometimes have profoundly decreased PT% values. Failure to account for DOAC interference could lead to mismanagement and errors in prioritizing patients for liver transplantation.
Authors
- Olivier Roux (ORCID: https://orcid.org/0000-0003-1563-7066)
- François Durand (ORCID: https://orcid.org/0000-0002-0357-1090)
- Catherine Trichet
- J. Gay
- Emmanuelle de Raucourt (ORCID: https://orcid.org/0000-0001-8774-3162)
- Imen Ben Salah
- Pierre‐Emmanuel Rautou (ORCID: https://orcid.org/0000-0001-9567-1859)
- Capucine Habay (ORCID: https://orcid.org/0009-0003-6225-2959)
- A. Riescher Tuczkiewicz
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de Recherche sur l'Inflammation (FR)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1016/j.rpth.2025.103289
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00